评论

The IntelliCAD^® Technology Consortium (ITC) today announced the release of IntelliCAD 13.0.

IntelliCAD 13.0 is a major release that includes performance improvements and new features, including a new Options dialog which is highly compatible with other CAD applications, calculators for evaluating expressions and converting units of measurement, lookup tables and the ability to reset advanced blocks, and digital signatures for .dwfx files. When creating reports, extract data from external references, advanced blocks, attributes, and AEC entities; extract from .dgn, .ifc, .rvt, and .rfa files if supported; and filter data to meet conditions.

LISP is completely refactored to improve performance and increase compatibility...

HCLTech, a leading global technology company, announced the launch of HCLTech Enterprise AI Foundry on Microsoft Azure, enabling enterprises to combine their data and AI assets with Microsoft's Azure Data & AI services to accelerate their GenAI-driven transformation journeys and time-to-value.

HCLTech Enterprise AI Foundry on Microsoft Azure enables streamlined operations and smart decision-making, accelerating time-to-value and driving positive business outcomes. Using Azure AI Studio, Azure OpenAI Service and Cognitive services, HCLTech’s Enterprise AI Foundry expedites AI solution development and deployment. It also assists in establishing an AI-ready data foundation, ensuring high-quality AI-powered data solutions.

"In the rapidly evolving technology and business...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience.

“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current...

Second quarter 2024

• 0 per cent organic revenue growth (using fixed exchange rates and a comparable group structure)
• Net sales decreased by -1 per cent to 1,353.4 MEUR (1,366.0)
• Net sales including the reduction of acquired deferred revenue amounted to 1,353.4 MEUR (1,365.0)
• Adjusted gross margin of 67.3 per cent (65.6)
• Adjusted operating earnings (EBIT1) increased by 1 per cent to 399.5 MEUR (394.1)
• Adjusted operating margin amounted to 29.5 per cent (28.9)
• Earnings per share, excluding adjustments, amounted to 10.8 Euro cent (10.8)
• Earnings per share, including adjustments, amounted to 9.6 Euro cent (9.4)
• Operating cash flow before non-recurring items increased to 248.5 MEUR (212.5)
• Cash conversion amounted to...

ASMPT and IBM announced a renewed agreement to extend their collaboration on the joint development of the next advancement of chiplet packaging technologies. Through the agreement, the two companies will work together to advance thermocompression and hybrid bonding technology for chiplet packages, using ASMPT’s next generation of Firebird TCB and Lithobolt hybrid bonding tools.

Chiplets deconstruct SOCs into their composite parts, creating smaller chips that can then be packaged together to operate as a single system, to provide potential benefits that can include improved energy efficiency, faster system development cycle time, and reduced costs. However, packaging advances are needed to move...